David Higley Spencer MD
Molecular Genetics, Anatomic Pathology, Clinical Pathology
Physician
Join to View Full Profile
660 S Euclid AveBox 8118Saint Louis, MO 63110
Phone+1 314-362-1454
Are you Dr. Spencer?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. David Spencer, MD is a board certified pathologist in Saint Louis, Missouri. He is currently licensed to practice medicine in Missouri.
Education & Training
Washington University/B-JH/SLCH ConsortiumFellowship, Molecular Genetic Pathology, 2013 - 2014- Washington University/B-JH/SLCH ConsortiumResidency, Pathology-Anatomic and Clinical, 2010 - 2013
University of Washington School of MedicineClass of 2010
Certifications & Licensure
MO State Medical License 2013 - 2026
American Board of Pathology Pathology - Clinical- American Board of Pathology Pathology - Molecular Genetic
Publications & Presentations
PubMed
- Missense Mutations in Myc Box I Influence Nucleocytoplasmic Transport to Promote Leukemogenesis.Nancy B J Arthur, Keegan A Christensen, Kathleen Mannino, Marianna B Ruzinova, Ashutosh Kumar
Clinical Cancer Research. 2024-08-15 - Molecular responses in decitabine- and decitabine/ venetoclax-treated patients with acute myeloid leukemia and myelodysplastic syndromes.Agata Gruszczynska, Abhishek Maiti, Christopher A Miller, Sai Mukund Ramakrishnan, Daniel C Link
Haematologica. 2024-08-01 - 1 citationsClinical whole-genome sequencing and FISH identify two different fusion partners for NUP98 in a patient with acute myeloid leukemia: A case report.Bahareh A Mojarad, Zachary D Crees, Molly C Schroeder, Zhifu Xiang, Justin Vader
Cancer Genetics. 2024-01-01
Press Mentions
Birthplace of Precision MedicineNovember 14th, 2024
Regulated Ex Vivo Regional Gene Therapy for Bone Repair Using an Inducible Caspase-9 Suicide Gene SystemApril 8th, 2019- Medicare Approves WashU Medicine’s Whole-Genome Test for Blood Cancers – Washington University School of Medicine in St. LouisAugust 21st, 2023
- Join now to see all
Grant Support
- Dysregulated genome architecture in acute myeloid leukemiaWASHINGTON UNIVERSITY2022–2027
- Dysregulated genome architecture in acute myeloid leukemiaWASHINGTON UNIVERSITY2022–2027
- A Rapid and Comprehensive Approach for Clinical Genomic Profiling in Lung CancerWASHINGTON UNIVERSITY2023–2026
- A Rapid and Comprehensive Approach for Clinical Genomic Profiling in Lung CancerWASHINGTON UNIVERSITY2023–2026
- A Rapid and Comprehensive Approach for Clinical Genomic Profiling in Lung CancerWASHINGTON UNIVERSITY2023–2026
- Genome sequencing for evaluating the efficacy, specificity, and safety of human genome editingWASHINGTON UNIVERSITY2023–2026
- A Rapid and Comprehensive Approach for Clinical Genomic Profiling in Lung CancerWASHINGTON UNIVERSITY2023–2026
- A Rapid and Comprehensive Approach for Clinical Genomic Profiling in Lung CancerWASHINGTON UNIVERSITY2023–2026
- Targeting apoptosis in high-risk AML and MDS with BCL-2 inhibitor Venetoclax and optimized 10-day Decitabine regimenALBERT EINSTEIN COLLEGE OF MEDICINE2019–2025
- Whole Genome Sequencing for Genomic Evaluation and Risk Stratification of Patients with Myelodysplastic SyndromesWASHINGTON UNIVERSITY2022–2024
